Connecting clients, partners and patients to develop new treatments for diabetes and related metabolic diseases.
Clinical Development and Regulatory Strategy + State-of-the-Art Clinical Facility + Full Scope CRO Services + Global Scientific Network
ProSciento and OWL Metabolomics Form Strategic Collaboration Focused on Accelerating NAFLD/NASH Clinical Trial Recruitment Read More »
ProSciento Appoints Dr. Kelvin Logan, Former Executive at INC Research and Quintiles, to its Board of Directors Read More »
View Our Presentation
NEJM article: Effects of 1x/weekly exenatide on CV outcomes in T2D Read More »
New CDC Data Shows US Adults Still Struggling with Obesity Read More »
FDA approves Novo Nordisk’s liraglutide for reduced risk of major CV events Read More »